Patents by Inventor Michael Eissenstat

Michael Eissenstat has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7157495
    Abstract: Compositions comprising bis-tetrahydrofuran benzodioxyolyl sulfonamide compounds that are surprisingly effective protease inhibitors and a second antiretroviral compound are disclosed. Methods of inhibiting retrovirus proteases, in particular multi-drug resistant retrovirus proteases, methods of treating or preventing infection or disease associated with retrovirus infection in a mammal, and methods of inhibiting viral replication are also disclosed.
    Type: Grant
    Filed: June 25, 2003
    Date of Patent: January 2, 2007
    Assignees: Tibotec Pharmaceuticals, Ltd., The United States of America as represented by the Department of Health and Human Services
    Inventors: Guangyang Wang, Michael Eissenstat, John W. Erickson, Piet T. B. P. Wigerinck
  • Publication number: 20060293286
    Abstract: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.
    Type: Application
    Filed: July 21, 2006
    Publication date: December 28, 2006
    Applicant: Sequoia Pharmaceuticals, Inc.
    Inventors: John Erickson, Michael Eissenstat, Abelardo Silva, Sergei Gulnik
  • Publication number: 20060258627
    Abstract: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.
    Type: Application
    Filed: July 21, 2006
    Publication date: November 16, 2006
    Applicant: Sequoia Pharmaceuticals
    Inventors: Michael Eissenstat, Andrey Topin, Greg Delahanty, Gnana Rajendran
  • Publication number: 20060258737
    Abstract: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.
    Type: Application
    Filed: July 21, 2006
    Publication date: November 16, 2006
    Applicant: Sequoia Pharmaceuticals, Inc.
    Inventors: John Erickson, Michael Eissenstat, Abelardo Silva, Sergei Gulnik
  • Patent number: 7132420
    Abstract: The present invention provides an aspartic proteinase-inhibiting compound of the formula: wherein a, b, c, d, and e, can be the same or different and each are R7, OR7, SR7, NR7R8, NHCOR7, CO2R7, CN, NO2, NH2, N3, or a halogen, wherein R7 and R8 are independently H or an alkyl. Substituents R1 or R2 are each H or an alkyl. Substituent R3 is a straight chain or branched alkyl, alkenyl, or alkynyl substituent, or is a cycloalkyl. Substituent A is OH, NH2, or SH. Further provided are pharmaceutical compositions, which include a therapeutically effective amount of at least one of the foregoing compounds, and therapeutic methods of using the foregoing compounds.
    Type: Grant
    Filed: June 11, 2003
    Date of Patent: November 7, 2006
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Ramnarayan S. Randad, John W. Erickson, Michael A. Eissenstat, Lucyna Lubkowska
  • Patent number: 7109230
    Abstract: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.
    Type: Grant
    Filed: January 7, 2003
    Date of Patent: September 19, 2006
    Assignee: Sequoia Pharmaceuticals, Inc.
    Inventors: John W. Erickson, Michael Eissenstat, Abelardo Silva, Sergei Gulnik
  • Publication number: 20060025594
    Abstract: The present invention concerns a compound having the formula (I) a N-oxide form, a stereochemical isomer, racemic mixture, salt, prodrug, ester or metabolite thereof. It further relates to processes for their preparation as well as pharmaceutical compositions, their use as medicines, and diagnostic kits comprising them. The present invention also concerns combinations of the present entry inhibitors with anti-retroviral agents. It further relates to their use in assays as reference compounds or as reagents. The compounds of the present invention are useful for preventing or treating infection by HIV and for treating AIDS.
    Type: Application
    Filed: March 11, 2003
    Publication date: February 2, 2006
    Applicant: TIBOTEC Pharmaceuticals Ltd.
    Inventors: Marie-Pierre De Bethune, Sandra De Meyer, Kurt Hertogs, Rong Lu, Lieve Michiels, Abdellah Tahri, Dong Xie, Michael Eissenstat
  • Publication number: 20050267074
    Abstract: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.
    Type: Application
    Filed: May 9, 2005
    Publication date: December 1, 2005
    Applicant: Sequoia Pharmaceuticals
    Inventors: Michael Eissenstat, Andrey Topin, Greg Delahanty, Gnana Rajendran
  • Publication number: 20050261364
    Abstract: Compositions comprising bis-tetrahydrofuran benzodioxyolyl sulfonamide compounds that are surprisingly effective protease inhibitors and a second antiretroviral compound are disclosed. Methods of inhibiting retrovirus proteases, in particular multi-drug resistant retrovirus proteases, methods of treating or preventing infection or disease associated with retrovirus infection in a mammal, and methods of inhibiting viral replication are also disclosed.
    Type: Application
    Filed: June 25, 2003
    Publication date: November 24, 2005
    Inventors: Guangyang Wang, Michael Eissenstat, John Erickson, Piet Wigerinck
  • Publication number: 20050209301
    Abstract: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.
    Type: Application
    Filed: March 11, 2005
    Publication date: September 22, 2005
    Applicant: SEQUOIA PHARMACEUTICALS
    Inventors: Michael Eissenstat, Tatiana Guerassina
  • Publication number: 20050107342
    Abstract: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.
    Type: Application
    Filed: January 7, 2003
    Publication date: May 19, 2005
    Inventors: John Erickson, Michael Eissenstat, Abelardo Silva, Sergei Gulnik
  • Publication number: 20050090546
    Abstract: The present invention provides an aspartic proteinase-inhibiting compound of the formula: wherein a, b, c, d, and e, can be the same or different and each are R7, OR7, SR7, NR7R7, NHCOR7, CO2R7, CN, NO2, NH2, N3, or a halogen, wherein R7 and R8 are independently H or an alkyl. Substituents R1 or R2 are each H or an alkyl. Substituent R3 is a straight chain or branched alkyl, alkenyl, or alkynyl substituent, or is a cycloalkyl. Substituent A is OH, NH2, or SH. Further provided are pharmaceutical compositions, which include a therapeutically effective amount of at least one of the foregoing compounds, and therapeutic methods of using the foregoing compounds.
    Type: Application
    Filed: June 11, 2003
    Publication date: April 28, 2005
    Applicant: Government of the USA, represented by the Secretary, Department of Health and Human Services
    Inventors: Ramnarayan Randad, John Erickson, Michael Eissenstat, Lucyna Lubkowska
  • Publication number: 20040009890
    Abstract: The invention features a method of designing broad spectrum inhibitors using structural data, compositions having broad spectrum activity, and methods for treating disease using those compositions.
    Type: Application
    Filed: January 7, 2003
    Publication date: January 15, 2004
    Inventors: John W. Erickson, Michael Eissenstat, Abelardo Silva, Sergei Gulnik
  • Patent number: 6649651
    Abstract: Novel bis-tetrahydrofuran benzodioxolyl sulfonamide compounds which are surprisingly effective protease inhibitors. The invention also relates to pharmaceutical compositions, methods of inhibiting retrovirus proteases, in particular multidrug resistant retrovirus proteases, methods of treating or combating infection or disease associated with retrovirus infection in a mammal, and methods of inhibiting viral replication.
    Type: Grant
    Filed: December 23, 2002
    Date of Patent: November 18, 2003
    Assignee: Tibotec Pharmaceuticals LTD
    Inventors: Piet T. B. P. Wigerinck, Guangyang Wang, Michael Eissenstat, John W. Erickson
  • Publication number: 20030171423
    Abstract: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.
    Type: Application
    Filed: January 7, 2003
    Publication date: September 11, 2003
    Inventors: John W. Erickson, Michael Eissenstat, Abelardo Silva, Sergei Gulnik
  • Patent number: 6613764
    Abstract: The present invention provides a compound of formula (I) wherein a, b, c, d, and e, are R7, OR7, SR7, NR7R8, NHCOR7, CO2R7, CN, NO2, NH2, N3, or a halogen. R7 and R8 are H or alkyl, R1 and R2 are H or alkyl, and R3 is a non-aromatic substituent. Substituent A is OH, NH2, or SH. Substituents B and B1 include amide and sulfonamide groups, which can be cyclic, acyclic, or amino acid derivatives. Alternatively, B and R′ together with the nitrogen to which they are bonded, and/or B′ and R2 together with the nitrogen to which they are bonded, define a heterocycle. The present invention further provides a pharmaceutical composition that includes a carrier and a therapeutically effective amount of at least one compound of the present invention.
    Type: Grant
    Filed: September 28, 2001
    Date of Patent: September 2, 2003
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Ramnarayan S. Randad, John W. Erickson, Michael A. Eissenstat, Lucyna Lubkowska
  • Patent number: 5750550
    Abstract: 2-(Pyrazol-5-yl-oxymethyl)-1,2-benzisothiazol-3(2H)-one 1,1-dioxides, pharmaceutical compositions containing them and methods for the treatment of degenerative diseases utilizing them.
    Type: Grant
    Filed: September 15, 1995
    Date of Patent: May 12, 1998
    Assignee: Sanofi
    Inventors: Michael A. Eissenstat, Gee-Hong Kuo, Ranjit C. Desai, Dennis J. Hlasta, John J. Court
  • Patent number: 5356903
    Abstract: Compounds of formula ##STR1## wherein; R.sub.1 is hydrogen, lower-alkyl, or trifluoromethyl;R.sub.2 is lower-alkyl, trifluoromethyl or CH.sub.2 X where X is hydroxy, chloro, lower-alkylamino or dilower-alkylamino;R.sub.3 and R.sub.4 are each individually hydrogen or fluoro;Z is NR.sub.5 or CR.sub.6 R.sub.7 ;R.sub.5 is hydrogen, aryl, arylthio, arylsulfonyl, lower-alkyl, cycloalkyl, heterocycloalkyl, amino-lower-alkyl, lower-alkylamino-lower-alkyl, dilower-alkylamino-lower-alkyl, lower-alkoxy, hydroxy or NR.sub.8 R.sub.9 ;R.sub.6 is hydrogen, cyano, lower-alkoxycarbonyl, lower-alkanoyl, nitro or lower-alkylsulfonyl;R.sub.7 is hydrogen, cyano, lower-alkoxycarbonyl, lower-alkanoyl, nitro, aryl, or lower-alkylsulfonyl;R.sub.8 is hydrogen, lower-alkyl, aryl, heterocycloalkyl, carbamyl, alkanoyl, aroyl, hydroxy-lower-alkyl; andR.sub.9 is hydrogen, lower-alkyl or lower-alkanoyl or pharmaceutically acceptable acid addition salts thereof are useful as anticancer agents.
    Type: Grant
    Filed: April 22, 1993
    Date of Patent: October 18, 1994
    Assignee: Sterling Winthrop Inc.
    Inventors: Michael A. Eissenstat, Gee-Hong Kuo
  • Patent number: 5330992
    Abstract: Compounds of formula ##STR1## wherein R.sub.1 is hydrogen, lower-alkyl, or trifluoromethyl;R.sub.2 is lower-alkyl, trifluoromethyl or CH.sub.2 Z where Z is hydroxy, chloro, lower-alkylamino or dilower-alkylamino;R.sub.3 and R.sub.4 are each individually hydrogen or fluoro; andAr is phenyl, an aromatic 5- or 6-membered heterocycle or any of these substituted at one or more positions with lower-alkyl, fluoro, chloro, hydroxy, amino, lower-alkylamino, dilower-alkylamino, carboxy, sulfonamido, lower alkylsulfonamido, methylenedioxy, trifluoroacetamido, lower-alkanoylamino, or carbamoyl; and their pharmaceutically acceptable acid addition salts are useful as anticancer agents.
    Type: Grant
    Filed: October 23, 1992
    Date of Patent: July 19, 1994
    Assignee: Sterling Winthrop Inc.
    Inventors: Michael A. Eissenstat, John D. Weaver, III, Gee-Hong Kuo, Mark P. Wentland
  • Patent number: 5324737
    Abstract: 2-R.sub.2 -R.sub.4 -substitutea-3-R.sub.3 -CO-1-[(C-attached-N-heteryl)(Alk).sub.n ]-1H-indoles useful as analgesic, anti-rheumatic, anti-inflammatory or anti-glaucoma agents.
    Type: Grant
    Filed: September 26, 1991
    Date of Patent: June 28, 1994
    Assignee: Sterling Winthrop Inc.
    Inventors: Thomas E. D'Ambra, Edward R. Bacon, Malcolm R. Bell, Philip M. Carabateas, Michael A. Eissenstat, Virendra Kumar, John P. Mallamo, Susan J. Ward